|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic,Pneumonia,and Severe Disease Caused by the Delta Variant:Real World Study and Evidence—China,2021显示文摘Summary What is already known about this topic?Effectiveness of China’s 2 inactivated vaccines(BBIBPCorV and CoronaVac)against pre-Delta severe acute respiratory syndrome coronavirus-2(SARS-CoV-2)variants ranged from 47%to over 90%,depending on the clinical endpoint,and with greater effectiveness against more severe coronavirus disease 2019(COVID-19).During an outbreak in Guangdong,inactivated vaccine effectiveness(VE)against the Delta variant was 70%for symptomatic infection and 100%for severe COVID-19.However,separate or combined VE estimates for the two inactivated vaccines against Delta are not available.What is added by this report?In an outbreak that started in a hospital,VEs of completed primary vaccination with inactivated COVID-19 vaccines against symptomatic COVID-19,COVID-19 pneumonia,and severe COVID-19 caused by the Delta variant were 51%,61%,and 82%.Completed primary vaccination reduced the risk of progressing from mild to moderate or severe COVID-19 by 74%.VE estimates for BBIBP-CorV and CoronaVac or combined vaccination were similar,and partial vaccination was ineffective.What are the implications for public health practice?Completed primary vaccination with either of the 2 inactivated COVID-19 vaccines reduces risk of symptomatic COVID-19,COVID-19 pneumonia,and severe COVID-19 caused by the Delta variant.Completion of the completed primary vaccination with two doses is necessary for protection from Delta. | Dan Wu Yanyang Zhang Lin Tang Fuzhen Wang Ying Ye Chao Ma Hui Zheng Wenzhou Yu Lei Cao Yifan Song Abuduwaili Reyimu Xiaoxiao Zhang Haifeng Wang Yifei Nie Mingxia Lu Muge Qi Jun Li Ruolin Wang Kaichao Yang Changshuang Wang Lawrence Everett Rodewald Geroge Fu Gao Zhijie An Zundong Yin | 2022 | China CDC weekly2022，4，4： | 7 |
| 2 | Enhanced remediation of Cr(Ⅵ)-contaminated groundwater by coupling electrokinetics with ZVI/Fe_(3)O_(4)/AC-based permeable reactive barrier显示文摘Although widely used in permeation reaction barrier(PRB)for strengthening the removal of various heavy metals,zero-valent iron(ZVI)is limited by various inherent drawbacks,such as easy passivation and poor electron transfer.As a solution,a synergistic system with PRB and electrokinetics(PRB-EK)was established and applied for the efficient removal of Cr(Ⅵ)-contaminated groundwater.As the filling material of PRB,ZVI/Fe_(3)O_(4)/activated carbon(ZVI/Fe_(3)O_(4)/AC)composites were synthesized by ball milling and thermal treatment.A series of continuous flow column experiments and batch tests was conducted to evaluate the removal efficiency of Cr(Ⅵ).Results showed that the removal efficiency of Cr(Ⅵ)remained above 93%even when the bed volume(BV)reached 2000 under the operational parameters(iron/AC mass ratio,2:1;current,5 m A).The mechanism of Cr(Ⅵ)removal by the PRB-EK system was revealed through field emission scanning electron microscopy images,X-ray diffraction,X-ray photoelectron spectroscopy,Fe^(2+) concentration,and redox potential(E h)values.The key in Cr(Ⅵ)reduction was the Fe^(2+)/Fe^(3+) cycle driven by the surface microelectrolysis of the composites.The application of an externally supplied weak direct current maintained the redox process by enhancing the electron transfer capability of the system,thereby prolonging the column lifetime.Cr(Ⅵ)chemical speciation was determined through sequential extraction,verifying the stability and safety of the system.These findings provide a scientific basis for PRB design and the in-situ remediation of Cr(Ⅵ)-contaminated groundwater. | Ruolin Cao Shiqing Liu Xinyu Yang Chunfeng Wang Yanbin Wang Wanfeng Wang Yunqing Pi | 2022 | Journal of Environmental Sciences2022，34，2： | 4 |
| 3 | Structure-guided discovery of potent and oral soluble epoxide hydrolase inhibitors for the treatment of neuropathic pain显示文摘Soluble epoxide hydrolase(sEH) is related to arachidonic acid cascade and is over-expressed in a variety of diseases, making sEH an attractive target for the treatment of pain as well as inflammatory-related diseases. A new series of memantyl urea derivatives as potent sEH inhibitors was obtained using our previous reported compound 4 as lead compound. A preferential modification of piperidinyl to 3-carbamoyl piperidinyl was identified for this series via structure-based rational drug design. Compound A20 exhibited moderate percentage plasma protein binding(88.6%) and better metabolic stability in vitro. After oral administration, the bioavailability of A20 was 28.6%. Acute toxicity test showed that A20 was well tolerated and there was no adverse event encountered at dose of 6.0 g/kg. Inhibitor A20 also displayed robust analgesic effect in vivo and dose-dependently attenuated neuropathic pain in rat model induced by spared nerve injury, which was better than gabapentin and sEH inhibitor(±)-EC-5026. In one word, the oral administration of A20 significantly alleviated pain and improved the health status of the rats, demonstrating that A20 was a promising candidate to be further evaluated for the treatment of neuropathic pain. | Fangyu Du Ruolin Cao Lu Chen Jianwen Sun Yajie Shi Yang Fu Bruce D.Hammock Zhonghui Zheng Zhongbo Liu Guoliang Chen | 2022 | Acta Pharmaceutica Sinica B2022，12，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员